Heparin Sodium
drugOn this page
Also known as Crude heparinCrude heparin porcineHeparin lock flushHeparin sodium component of defencathHeparin sodium component of embolexHeparin sodium porcineHeparin sodium preservative freeHeparin sodium unfractionatedporcineHeparina de sodioHeparine sodiqueHeparinum natricumLipo-hepinLiquaemin lock flushLiquaemin sodiumLiquaemin sodium preservative freeLiquemin sodiumMultiparinPanheprin
Summary
Heparin Sodium (CHEMBL1201657) is an approved oligosaccharide targeting SERPINC1; indicated across 13 conditions including pulmonary embolism and atrial fibrillation.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Oligosaccharide
- Targets: 1 (SERPINC1)
- Indications: 13 conditions
- Clinical trials: 15
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201657 |
| Name | Heparin Sodium |
| Type | Oligosaccharide |
| Max phase | 4 |
Also known as: Crude heparin, Crude heparin porcine, Heparin lock flush, Heparin sodium, Heparin sodium component of defencath, Heparin sodium component of embolex, Heparin sodium porcine, Heparin sodium preservative free, Heparin sodium unfractionated, porcine, Heparina de sodio, Heparine sodique
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| SERPINC1 | serpin family C member 1 | Activation | 7.85 | 0% | P01008 |
| CoV Spike glycoprotein | Binding | 9 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): SERPINC1.
Top Reactome pathways
12 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Hemostasis | 1 | SERPINC1 |
| R-HSA-140837 | 1 | SERPINC1 |
| R-HSA-140875 | 1 | SERPINC1 |
| R-HSA-140877 | 1 | SERPINC1 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 1 | SERPINC1 |
| Metabolism of proteins | 1 | SERPINC1 |
| Post-translational protein modification | 1 | SERPINC1 |
| Post-translational protein phosphorylation | 1 | SERPINC1 |
| Fibrin formation | 1 | SERPINC1 |
| Initiation of coagulation cascade | 1 | SERPINC1 |
| Regulation of clotting cascade | 1 | SERPINC1 |
| Amplification and propagation of coagulation cascade | 1 | SERPINC1 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| blood coagulation | 1 |
| regulation of blood coagulation | 1 |
| hemostasis | 1 |
Indications & clinical
Indications
13 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| pulmonary embolism | 4 | MONDO:0005279 | EFO:0003827 |
| atrial fibrillation | 4 | MONDO:0004981 | EFO:0000275 |
| venous thromboembolism | 3 | MONDO:0005399 | EFO:0004286 |
| acute kidney injury | 3 | MONDO:0002492 | HP:0001919 |
| hip fracture | 3 | MONDO:0005327 | EFO:0003964 |
| thrombotic disease | 3 | MONDO:0000831 | MONDO:0000831 |
| type 2 diabetes mellitus | 3 | MONDO:0005148 | MONDO:0005148 |
| colorectal neoplasm | 3 | MONDO:0005335 | MONDO:0005575 |
| chronic kidney disease | 3 | MONDO:0005300 | MONDO:0024327 |
| severe acute respiratory syndrome | 1 | MONDO:0005091 | MONDO:0100096 |
3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 15.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 5 |
| PHASE3 | 3 |
| Not specified | 3 |
| PHASE1/PHASE2 | 2 |
| PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03113708 | PHASE4 | UNKNOWN | The Effect of Heparinization Due to LBW |
| NCT03539718 | PHASE4 | UNKNOWN | Taurolock Hep 500 Versus Unfractionated Heparin as Anti-inflammatory in Hemodialysis Catheters. |
| NCT04530578 | PHASE4 | UNKNOWN | Nebulized Heparin in Severe Acute Respiratory Syndrome COVID-19 |
| NCT05697692 | PHASE4 | UNKNOWN | Heparin-free Extracorporeal Membrane Oxygenation Support During Clinical Lung Transplantation |
| NCT06646328 | PHASE4 | TERMINATED | Oxidative Stress and Circulating Nuclear DNA (cfDNA) in Acute Kidney Injury and Continuous Renal Replacement Therapies. |
| NCT00427310 | PHASE3 | COMPLETED | Liver Infusions of Fluorouracil in Treating Patients With Dukes’ A, Dukes’ B, or Dukes’ C Colon Cancer Undergoing Surgery |
| NCT01346215 | PHASE3 | UNKNOWN | Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure |
| NCT02654561 | PHASE3 | UNKNOWN | Efficacy and Safety of Unfractionated Heparin on Severe Sepsis With Suspected Disseminated Intravascular Coagulation |
| NCT02206087 | PHASE1/PHASE2 | COMPLETED | Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PER977 Following Heparin |
| NCT04743011 | PHASE1/PHASE2 | COMPLETED | Enriched Heparin Anti COVID-19 Trial |
| NCT05602129 | PHASE2 | UNKNOWN | A Clinical Study to Evaluate the Efficacy, Safety and PK/PD Profiles of Anticoagulation of HSK36273 for Injection in Continuous Renal Replacement Therapy Subjects |
| NCT03707418 | PHASE1 | WITHDRAWN | Bivalirudin vs Heparin in ECMO Patients |
| NCT03306836 | Not specified | UNKNOWN | Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation 2 |
| NCT04767113 | Not specified | COMPLETED | Continuous Heparin Infusion to Prevent Catheter-related Thrombosis |
| NCT05749393 | Not specified | UNKNOWN | Effect of Different Heparinization Schemes on Prognosis of Intracranial Aneurysm |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
2 molecules share ≥1 primary target. Top 2 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| IDRAPARINUX | ChEMBL | Phase 3 | SERPINC1 |
| fondaparinux | PubChem | Approved | SERPINC1 |